title: Novel molecular mechanism involving alpha1D (Cav1.3) L-type calcium channel in autoimmune-associated sinus bradycardia.
abstract: BACKGROUND
  Congenital heart block (CHB) is an autoimmune disease that affects fetuses/infants born to mothers with anti-Ro/La antibodies (positive IgG). Although the hallmark of CHB is complete atrioventricular block, sinus bradycardia has been reported recently in animal models of CHB. Interestingly, knockout of the neuroendocrine alpha1D Ca channel in mice results in significant sinus bradycardia and atrioventricular block, a phenotype reminiscent to that seen in CHB. Here, we tested the hypothesis that the alpha1D Ca channel is a novel target for positive IgG.
  
  
  RESULTS
  Reverse transcription-polymerase chain reaction, confocal indirect immunostaining, and Western blot data established the expression of the alpha1D Ca channel in the human fetal heart. The effect of positive IgG on alpha1D Ca current (I(Ca-L)) was characterized in heterologous expression systems (tsA201 cells and Xenopus oocytes) because of the unavailability of alpha1D-specific modulators. alpha1D I(Ca-L) activated at negative potentials (between -60 and -50 mV). Positive IgG inhibited alpha1D I(Ca-L) in both expression systems. This inhibition was rescued by a Ca channel activator, Bay K8644. No effect on alpha1D I(Ca-L) was observed with negative IgG and denatured positive IgG. Western blot data showed that positive IgG binds directly to alpha1D Ca channel protein.
  
  
  CONCLUSIONS
  The data are the first to demonstrate (1) expression of the alpha1D Ca channel in human fetal heart, (2) inhibition of alpha1D I(Ca-L) by positive IgG, and (3) direct cross-reactivity of positive IgG with the alpha1D Ca channel protein. Given that alpha1D I(Ca-L) activates at voltages within the pacemaker's diastolic depolarization, inhibition of alpha1D I(Ca-L) in part may account for autoimmune-associated sinus bradycardia. In addition, Bay K8644 rescue of alpha1D I(Ca-L) inhibition opens new directions in the development of pharmacotherapeutic approaches in the management of CHB.
authors.affiliation: VA New York Harbor Healthcare System, New York, NY, USA.
authors.forename: Yongxia
authors.initials: Y
authors.lastname: Qu
authors.forename: Ghayath
authors.initials: G
authors.lastname: Baroudi
authors.forename: Yuankun
authors.initials: Y
authors.lastname: Yue
authors.forename: Mohamed
authors.initials: M
authors.lastname: Boutjdir
mesh_terms: D000818:Animals; D001323:Autoantibodies; D001327:Autoimmune Diseases / Q000150:complications*; D001919:Bradycardia / Q000209:etiology* / Q000276:immunology; D002118:Calcium / Q000378:metabolism; D020746:Calcium Channels, L-Type / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D002460:Cell Line; D004594:Electrophysiology; D005333:Fetus / Q000166:cytology; D006321:Heart / Q000503:physiopathology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D032383:Myocytes, Cardiac / Q000737:chemistry / Q000502:physiology; D012333:RNA, Messenger / Q000032:analysis; D011817:Rabbits; D012849:Sinoatrial Node / Q000503:physiopathology; D014161:Transduction, Genetic
chemical_list: D001323:Autoantibodies; C472073:CACNA1D protein, human; D020746:Calcium Channels, L-Type; D007074:Immunoglobulin G; D012333:RNA, Messenger; D002118:Calcium